Skip to content

Non-prescription Versus Prescription Topical Treatments Versus no Treatment in the Control of Sweating

Non-prescription Versus Prescription Topical Treatments Versus no Treatment in the Control of Sweating

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00509886
Enrollment
24
Registered
2007-08-01
Start date
2007-06-30
Completion date
2007-08-31
Last updated
2014-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Excess Sweating, Hyperhidrosis

Brief summary

The purpose of this study is to assess the effectiveness of the prescription treatment compared to the non-prescription treatment. It is hypothesized that the prescription treatment will have a significantly greater effect than the non-prescription treatment on decreasing excess sweating.

Detailed description

The objective of this study is to assess the effectiveness of the prescription treatment compared to the non-prescription treatment. It is hypothesized that the prescription treatment will have a significantly greater effect than the non-prescription treatment on decreasing excess sweating.

Interventions

DRUGDrysol

20% aluminum chloride hexahydrate

DRUGDrioff

1% aluminum acetate

Sponsors

Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
21 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* age 21-30 years * males and females * The subjects are in good health. * The subjects have willingness and the ability to understand and provide informed consent for participation in the study.

Exclusion criteria

* Subjects with primary hyperhidrosis * Subjects who are unable to withstand prolonged heat exposure or who have self-reported history of cardiovascular or respiratory disorders. * Subjects who are unable to give informed consent. * Subjects with mental illness. * Subjects who are pregnant or nursing. * Subjects with systemic or local skin disease and/or infection that may interfere with the conduct of the study.

Design outcomes

Primary

MeasureTime frame
Gravimetric analysis3 hours

Secondary

MeasureTime frame
Subject sweat assessment3 hours
HDSS3 hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026